Home » Newsletters » BioWorld Science

BioWorld Science

July 9, 2007

View Archived Issues

Recent patents report new antidepressive and antipsychotic agents

Recent Pentapharm patent reports novel agents for disorders related to abnormal blood coagulation

New antidiabetic agents imparted in recent Amgen and Merck & Co. patents

Novel antiinflammatory agents disclosed in recent patent literature

Recent GE patents report new diagnostic agents

Depomed reacquires rights to ProQuin XR

Kaken and GTS sign agreement to develop alpha-9 antibodies

Data show efficacy benefit of Menopur compared to recombinant FSH treatment

HF-0220 shows utility in preclinical rheumatoid arthritis study

SuperGen reports dosing of first patient in phase I trial of novel TKI

EMEA approves Kamada's phase II/III trials of inhaled AAT in congenital emphysema

Novel CB1 receptor ligand with potential for human PET brain imaging

CSA-13 tested against infections in cystic fibrosis

Circadin approved in E.U. for primary insomnia

Swiss approval for DCVax-Brain

Canadian approval for Seasonale

First approval for Exelon Patch

Genzyme reports Hylastan phase III trials results for OA of the knee

Pharmaxis completes efficacy study of phase III trial of Bronchitol

Santaris Pharma Consortium awarded grant to develop first microRNA medicine

Genaera discontinues studies of Lomucin and squalamine

ViroPharma begins phase III trials of Camvia for CMV disease

NU-172: a potent and short-acting anticoagulant with potential use in cardiovascular surgery

diaDexus reports on Lp-PLA2's role in ischemic stroke risk evaluation

Phase I study results encourage further assessment of antiplatelet agent PR-15

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...